Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective was to assess the effect of 3-month treatment of low and standard doses of fenofibrate in combination with stable dose of metformin on fasting triglycerides levels in patients with type 2 diabetes and dyslipidemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| fenofibrate and metformin combination (drug) | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change in fasting triglycerides. |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of lipid and glucose metabolisms. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Director Solvay | Solvay Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site 201 | Katowice | Poland | ||||
| Site 203 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Katowice |
| Poland |
| Site 202 | Warsaw | Poland |
| Site 204 | Zabrze | Poland |
| Site 111 | Dnipropetrovsk | Ukraine |
| Site 113 | Dnipropetrovsk | Ukraine |
| Site 108 | Kharkiv | Ukraine |
| Site 109 | Kharkiv | Ukraine |
| Site 101 | Kyiv | Ukraine |
| Site 102 | Kyiv | Ukraine |
| Site 103 | Kyiv | Ukraine |
| Site 104 | Kyiv | Ukraine |
| Site 105 | Kyiv | Ukraine |
| Site 106 | Kyiv | Ukraine |
| Site 107 | Kyiv | Ukraine |
| Site 112 | Zaporizhya | Ukraine |
| Site 35 | Acomb | United Kingdom |
| Site 21 | Atherstone | United Kingdom |
| Site 14 | Balsall Common | United Kingdom |
| Site 32 | Bangor | United Kingdom |
| Site 23 | Barry | United Kingdom |
| Site 36 | Basingstoke | United Kingdom |
| Site 8 | Bexhill-on-Sea | United Kingdom |
| Site 20 | Camberley | United Kingdom |
| Site 22 | Chesterfield | United Kingdom |
| Site 10 | Chippenham | United Kingdom |
| Site 13 | Coventry | United Kingdom |
| Site 31 | Doncaster | United Kingdom |
| Site 15 | Downpatrick | United Kingdom |
| Site 17 | Ely | United Kingdom |
| Site 4 | Ely | United Kingdom |
| Site 11 | Fife | United Kingdom |
| Site 1 | Frome | United Kingdom |
| Site 16 | Harrow | United Kingdom |
| Site 5 | Hastings | United Kingdom |
| Site 26 | Haverfordwest | United Kingdom |
| Site 19 | Keresley End | United Kingdom |
| Site 9 | Kingswood | United Kingdom |
| Site 25 | Newtownabbey | United Kingdom |
| Site 33 | Northampton | United Kingdom |
| Site 28 | Odiham | United Kingdom |
| Site 3 | Paignton | United Kingdom |
| Site 12 | Peterborough | United Kingdom |
| Site 7 | Randalstown | United Kingdom |
| Site 27 | Slough | United Kingdom |
| Site 6 | Soham | United Kingdom |
| Site 2 | South Glamorgan | United Kingdom |
| Site 34 | Stratford-upon-Avon | United Kingdom |
| Site 29 | Swindon | United Kingdom |
| Site 30 | Trowbridge | United Kingdom |
| Site 18 | Yaxley | United Kingdom |
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| D044882 | Glucose Metabolism Disorders |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D011345 | Fenofibrate |
| D004364 | Pharmaceutical Preparations |
| ID | Term |
|---|---|
| D058607 | Fibric Acids |
| D058610 | Isobutyrates |
| D002087 | Butyrates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010647 | Phenyl Ethers |
| D004987 | Ethers |
| D001577 | Benzophenones |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D010636 | Phenols |
| D007659 | Ketones |
Not provided
Not provided